SCHEMBL6622908

SCHEMBL6622908

O=C(O)c1ccc(-c2cc[nH]n2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 2/20 0.52
TSHR P16473 1/20 0.47
CASP1 P29466 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PDK2 Q15119 1/20 0.41
KMO O15229 7/20 0.40
DHODH Q02127 1/20 0.40
MYC P01106 1/20 0.39
NR4A1 P22736 1/20 0.39
CA12 O43570 1/20 0.39
ALPL P05186 1/20 0.39
ALDH1A1 P00352 1/20 0.38
KDM5A P29375 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38
PRKAB2 O43741 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAA1 Q13131 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256795 0.88 XDH (0.52) XDHKMODHODHCA12ALPL
SCHEMBL6615920 0.84 PDK2 (0.46) SMN1; SMN2PDK2ALPL
SCHEMBL23535854 0.81 BTK (0.45) KMOCA12ALPLAKR1C2AKR1C1
SCHEMBL4503149 0.79 ACMSD (0.53) XDHCA12
SCHEMBL4515506 0.78 KMO (0.40) KMOCA12ALPL
SCHEMBL1829344 0.78 AHR (0.50) KMOALDH1A1
SCHEMBL2770320 0.77 TSHR (0.68) XDHTSHRCASP1SMN1; SMN2PDK2
SCHEMBL16627909 0.77 ESR2 (0.47) TSHR
SCHEMBL31518805 0.75 DHODH (0.40) DHODHCA12ALPLALDH1A1KDM4C
SCHEMBL6787087 0.73 ALDH1A1 (0.46) TSHRKMOALPLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 EP claimed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 WO claimed
US-6831079-B1 Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone AMERICAN CYANAMID COMPANY 2004-12-14 US disclosed
EP-1000062-B1 TRICYCLIC VASOPRESSIN AGONISTS WYETH CORP (US) 2004-09-22 EP disclosed
US-6511974-B1 Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure WYETH 2003-01-28 US disclosed
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 EP disclosed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 WO disclosed
EP-1000062-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
EP-1000012-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 2000-05-17 EP disclosed
US-5932745-A HYDROXYLIC SOLVENT AMERICAN HOME PRODUCTS CORPORATION (US) 1999-08-03 US disclosed
WO-1999006409-A1 TRICYCLIC VASOPRESSIN AGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed
WO-1999006351-A1 PROCESS FOR CONVERTING PROPARGYLIC AMINE-N-OXIDES TO ENAMINONES AMERICAN HOME PRODUCTS CORPORATION (US) 1999-02-11 WO disclosed